Price Alert

Celldex Therapeutics Inc. (CLDX)

NASDAQ: CLDX · Real-Time Price · USD

22.78

-0.83 (-3.52%)

At close: Sep 04, 2025, 3:59 PM

22.78

0.00%

After-hours: Sep 04, 2025, 05:59 PM EDT

-3.52% (1D)

Bid	22.18
Market Cap	1.51B
Revenue (ttm)	5.79M
Net Income (ttm)	-199.61M
EPS (ttm)	-3.01
PE Ratio (ttm)	-7.57
Forward PE	-5.34
Analyst	Buy

Ask	24.35
Volume	1,420,391
Avg. Volume (20D)	1,215,788
Open	23.52
Previous Close	23.61
Day's Range	22.34 - 23.57
52-Week Range	14.40 - 47.00
Beta	1.22

About CLDX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CLDX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CLDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Celldex Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

-13.03%

Celldex Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

2 weeks ago

-1.88%

Celldex Therapeutics shares are trading lower. The company reported Phase 2 topline results for Barzolvolimab in Eosinophilic Esophagitis.

News

2 weeks ago · seekingalpha.com

Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track

Celldex Therapeutics, Inc.'s barzolvolimab failed to improve symptoms in eosinophilic esophagitis, but this setback doesn't impact its promising ongoing urticaria programs. Phase 3 trials for chronic ...

2 weeks ago · benzinga.com

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short

On Tuesday, Celldex Therapeutics, Inc. CLDX released topline results from its ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.

4 weeks ago · zacks.com

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.54 per share a year ago.